Introduction
============

The notion that noradrenaline plays a key role in the etiology of depression and in the mechanism of action of antidepressants dates from the earliest days of the psychopharmacology era, and formed the basis for the catecholamine hypothesis of affective disorders ([@b29]). It was based on clinical observations that drugs that depleted noradrenaline and other brain monoamines lowered mood, while agents that enhanced the availability of brain monoamines improved mood and reversed the symptoms of depression. The original catecholamine hypothesis was soon modified to include a complementary role for serotonin as it was realized that traditional antidepressants, such as the tricyclics (TCAs) and the monoamine oxidase inhibitors (MAOIs), increased the levels of both noradrenaline and serotonin in the brain by blocking their reuptake or metabolic degradation, respectively ([@b7]). There are currently a large number of effective antidepressants of various classes, diverse structures, and different mechanisms of action available for clinical use ([Table 1](#tbl1){ref-type="table"}). Many of the original TCAs of the first generation were aselective in neurochemical action in that they inhibited reuptake of both monoamines, although desipramine, nortriptyline, and protriptyline were selective for noradrenaline, and clomipramine was somewhat selective for serotonin. For many years, maprotiline and viloxazine represented the last selective inhibitors of noradrenaline reuptake in an era that was dominated by research on the role of serotonin in depression and the development of selective serotonin reuptake inhibitors (SSRIs) as antidepressants ([@b24], [@b25]). Although noradrenaline still had its place in the mechanism of action of the α~2~-adrenoceptor antagonist mianserin, many of the other early second generation antidepressants such as trazodone, nefazodone, and the various SSRIs were based upon serotonergic mechanisms ([@b26]). While second generation antidepressants like the SSRIs have enjoyed wide popularity due to their more selective pharmacology and consequent improved tolerability and lesser toxicity than their first generation counterparts, there have been lingering doubts about their efficacy and onset of action, particularly in the more severely depressed and melancholic patients ([@b3]). The introduction of newer second generation antidepressants, like the serotonin noradrenaline reuptake inhibitors (SNRIs), exemplified by venlafaxine, and the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine, has demonstrated that it is possible to regain the dual pharmacological action and accompanying efficacy of the TCAs, while retaining the greater tolerability and lesser toxicity of the SSRIs ([@b20]; [@b31]).

###### 

Currently available antidepressants[a](#tf1-1){ref-type="table-fn"}

  Group   Drug            Group       Drug
  ------- --------------- ----------- ---------------------------------------------
  TCAs    Amitriptyline   MAOIs       Iproniazid
          Amoxapine                   Isocarboxazid
          Butriptyline                Moclobemide[b](#tf1-2){ref-type="table-fn"}
          Clomipramine                Phenelzine
          Desipramine                 Tranylcypromine
          Dibenzepin                  
          Dimetacrin      SSRIs       Citalopram
          Dothiepin                   Escitalopram
          Doxepin                     Fluoxetine
          Imipramine                  Fluvoxamine
          Iprindole                   Paroxetine
          Lofepramine                 Sertraline
          Maprotiline                 
          Melitracen      NaSSA       Mirtazapine
          Nortriptyline               
          Opipramol       NRIs        Reboxetine
          Protriptyline               Viloxazine
          Trimipramine                
  SNRIs   Duloxetine      Atypicals   Bupropion[c](#tf1-3){ref-type="table-fn"}
          Milnacipran                 Mianserin
          Venlafaxine                 Nefazodone
                                      Trazodone

Many of these drugs are either not available in the USA or are approved for indications other than depression.

Moclobemide is the only marketed example of a reversible inhibitor of the A-form of MAO (RIMA).

Not currently available in Europe as antidepressants.

**Abbreviation:** TCAs, tricyclic antidepressants; SNRIs, serotonin-noradrenaline reuptake inhibitors; MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin noradrenaline reuptake inhibitors; NaSSA, noradrenergic and specific serotonergic antidepressant; NRIs, selective noradrenaline reuptake inhibitors.

Enhancing central noradrenergic function in depression
======================================================

Noradrenaline as a specific target for treating depression, as opposed to being part of a multiple target approach, has become more fashionable in recent years with the development of the selective noradrenaline reuptake inhibitors (NRIs), eg reboxetine ([@b5]). In the clinical setting, selective NRIs may be advantageous in terms of short- and long-term efficacy in both moderate and severe depression, while acting to improve energy, interest, and motivation in depressed patients. However, like earlier tricyclic examples of the genre, such as desipramine, nortriptyline, maprotiline, and lofepramine ([Table 1](#tbl1){ref-type="table"}), and unlike the dual-action SNRIs and mirtazapine, the efficacy of reboxetine is not superior to that of SSRIs ([@b5]). Reboxetine is not yet approved in the USA as a result of a series of failed clinical trials in which neither it nor the active reference antidepressant were shown to be statistically significantly different in efficacy from placebo. A similar fate befell an earlier NRI, the tetracyclic Org 4428 ([@b26]; [@b19]). Such failures have prompted proposals to improve the ways in which clinical trials are performed to evaluate the efficacy and onset of action of new antidepressants ([@b12]; [@b18]). Reboxetine is an example of the designer's approach to new antidepressants; it has a structure not dissimilar to that of the older non-tricyclic NRI viloxazine, without the structural features that are associated with classical TCA-like side effects ([@b22], [@b23]). It may represent the last in a long line of NRIs for depression ([@b26]), since there do not appear to be any more of its ilk in clinical development at this time ([@b4]). Atomoxetine, like reboxetine, is a highly selective NRI that was previously in development as tomoxetine for depression ([@b26]), and has been reincarnated as a treatment for attention deficit hyperactivity disorder (ADHD) ([@b1]).

In addition to inhibiting the reuptake of noradrenaline, there are other ways to enhance its synaptic availability. The most notable is by blocking the α~2~-noradrenergic receptors located at the cell body, which control cell firing, or those at the synaptic terminal, which act as autoreceptors to regulate release. Two currently available antidepressants, mianserin and mirtazapine, do this as part of multiple pharmacological actions. The more potent α~2~-adrenoceptor antagonist idazoxan acts more selectively, but it has not been convincingly shown to be antidepressant ([@b21]). Of these three agents, only mirtazapine additionally enhances central serotonergic function via stimulation of facilitatory α~1~-adrenoceptors located on the cell bodies of raphe neurons and blockade of α~2~-heteroreceptors located on serotonergic nerve terminals, thereby endowing it with the familiar dual action upon both neurotransmitters ([@b8]). As with NRIs the development of new selective α~2~-adrenoceptor antagonists for depression has effectively stopped ([Table 2](#tbl2){ref-type="table"}). There is still some interest in mimicking the dual action of mirtazapine by combining α~2~-antagonism with other antidepressant-like pharmacology in the same molecule, eg 5-HT~1A~-agonism (sunepitron), and with SSRI (A 80426) or NRI (napitane) properties. Another putative antidepressant, napamezole, combines α~2~-antagonism with inhibition of the reuptake of three monoamines -- noradrenaline, serotonin, and dopamine. Inconclusive efficacy data have been reported for many of these compounds, and none of them seem to be in active clinical development ([@b21]; [@b4]).

###### 

α~2~-adrenoceptor antagonists as antidepressants

  Compound                                                                        Status              Neurotransmitter affected
  ------------------------------------------------------------------------------- ------------------- ---------------------------
  *α~2~-antagonists with multiple pharmacology*                                                       
  Mianserin                                                                       Marketed            NA
  Mirtazapine                                                                     Marketed            NA/5-HT
  Setiptiline                                                                     Marketed in Japan   NA
  *Selective α~2~-antagonists*                                                                        
  Idazoxan                                                                        Stopped             NA
  Fluparoxan                                                                      Stopped             NA
  *Selective α~2~-antagonists with additional antidepressant-like pharmacology*                       
  Napitane                                                                        Stopped             NA
  A 80426                                                                         Stopped             NA/5-HT
  Napamezole                                                                      Stopped             NA/5-HT/DA
  Sunepitron                                                                      Stopped             NA/5-HT

**Abbreviation:** NA, noradrenaline; 5-HT, serotonin; DA, dopamine.

The future for noradrenergic antidepressants
============================================

Is there a role for a pure noradrenergic drug in the treatment of depression ([@b17])? This question is particularly pertinent in an era when dual-action antidepressants affecting both noradrenergic and serotonergic systems, including the newly approved SNRI duloxetine, have demonstrated faster and more substantial effects than SSRIs on response and remission. Moreover, research on new antidepressants has largely moved away from monoamines and their receptors to focus on neurokinins, excitatory amino acids, neuronal plasticity, gene transcription factors, and the hypothalamic-pituitary-adrenal (HPA) axis ([@b30]; [@b4]; [@b23]). Furthermore, there is some evidence that combining noradrenergic agents like desipramine or mianserin with an SSRI to make a two-component dual-action treatment actually improves response (see [@b4]). Nevertheless, the single-action SSRIs as a group are still very widely used, while the latest antidepressant introductions include not only duloxetine but also the SSRI escitalopram ([Table 1](#tbl1){ref-type="table"}).

There is substantial preclinical and clinical evidence that noradrenaline plays a key role in the etiology of depressive disorders ([@b21]; [@b13]; [@b5]). Perhaps the most compelling arguments come from depletion studies in recently remitted depressed patients. Those patients who responded to, and continued to take, NRIs were more vulnerable to transient reversal of their response when given the catecholamine depleter α-methyl-para-tyrosine (AMPT). Responders to SSRIs were more vulnerable to tryptophan depletion, which reduces brain serotonin ([@b10]). The implication that there may be distinct roles for noradrenaline and serotonin in depression is not, however, entirely borne out by later observations from the same research group. Responders to the dual-action NaSSA mirtazapine were as likely to experience transient deterioration in mood when receiving either alpha-methyl-para-tyrosine (AMPT) or undergoing tryptophan depletion ([@b9]). Furthermore, the roles of the central noradrenergic and serotonergic systems may be inextricably linked in the etiology of depression, and in the mechanism of action of antidepressants both in the hippocampus ([@b16]) and frontal cortex ([@b15]). Even reboxetine seems to have an effect upon serotonergic neurotransmission in rat hippocampus, activating postsynaptic 5-HT~1A~ receptors by a desensitization of α~2~-adrenergic heteroreceptors resulting from sustained inhibition of noradrenaline reuptake ([@b32]).

Opportunities do exist to design more specific agents to affect noradrenergic function in depression ([@b21]; [@b28]). Thus, the fine molecular structure of the noradrenaline transporter, which mediates reuptake of the neurotransmitter, has long been characterized as belonging to a large family of membrane proteins all having 12 hydrophobic membrane spanning domains with the amino terminal and the carboxyl terminal ends of the polypeptide located intracellularly ([@b2]). The transcriptional gene for the noradrenaline transporter has also been identified ([@b27]), and human polymorphisms are known ([@b33]). Studies on chimeric dopamine-noradrenaline transporters have demonstrated that the binding domains for the tricyclic NRIs nortriptyline and desipramine are located in a different region from those for the neurotransmitter substrates ([@b11]). It may well be possible to design more regioselective inhibitors of noradrenaline reuptake than have presently been evaluated as antidepressants, and it is interesting that contrary to expectations and previous experience with most psychotropic drugs, compounds lacking nitrogen in their structure are capable of inhibiting the noradrenaline transporter ([@b14]).

α~2~-adrenoceptors have also been cloned and characterized ([@b6]). Three human genes located on chromosomes 10, 2, and 4 encode unique α~2~-adrenoceptor subtypes, which are characterized pharmacologically as α~2A~, α~2B~, and α~2C~, respectively. The α~2D~-subtype, found in the rat and other animal species but not in humans, seems to be a species variant of the human α~2A~-adrenoceptor. It is likely that noradrenergic neurons express predominantly the same gene across all mammalian species, the α~2A/D~-ortholog, to control transmitter release through presynaptic autoreceptors. The α~2A~-adrenoceptor is also the predominant subtype present in human blood platelet and cortex (see [@b21]). Neither the tetracyclic antidepressants mianserin, setiptiline, and mirtazapine, nor the more potent but putative antidepressants idazoxan and fluparoxan are selective for any of the α~2~-adrenoceptor subtypes, so it is entirely possible that highly selective agents could be developed ([@b21]; [@b28]).

Little research effort has gone into evaluating post-synaptic noradrenergic agonists as antidepressants, unlike the extensive investigations into postsynaptic 5-HT~1A~- agonists. Two decades ago, the β~2~-adrenoceptor agonist salbutamol and its more lipophilic cousin clenbuterol, which are used as bronchodilators in the treatment of asthma, enjoyed a brief vogue as putative antidepressants both in their own right and as adjuncts to TCAs: both were found wanting in efficacy and peripheral side effects ([@b28]). In more recent times, modafinil, an α~1~-agonist and central stimulant indicated for the treatment of narcolepsy, has become popular as an augmentation agent when standard antidepressants give an insufficient therapeutic response.

As a final note, the opportunities for finding new NRIs and ligands for the various types of noradrenergic receptors have been considerably enhanced by the modern pharmaceutical technologies of combinatorial chemistry and high-throughput screening ([@b23]). While such methods are potentially inhibitory to true innovation, in the sense that the biological assays are simple and usually based on known and proven technology, they are ideal for this type of opportunity. Many very large and diverse chemical libraries exist which could be screened in assays for the noradrenaline transporter and the different types of noradrenergic receptor. Any desired combination of such properties is also possible.

Conclusions
===========

There is no doubt that some effective antidepressants act principally through central noradrenergic mechanisms, and that noradrenaline plays an important role in the etiology of depressive disorders. Antidepressants with a noradrenergic component to their pharmacology may produce superior efficacy in severely depressed patients and those with melancholia, but there is no evidence that selective NRIs are any better than SSRIs except possibly in the arena of energy, interest, and motivation. Rather, it is the older dual-action TCAs and their modern counterparts the SNRIs and mirtazapine, which seem to have set the current standard in faster onset of action and greater degrees of response and remission.

Despite the recent flurry of interest in reboxetine, and the undoubted opportunities that exist for designing new NRIs and novel agents to affect noradrenergic receptors, there are no new antidepressants on the horizon that act principally through noradrenaline. There remains a stronger interest in serotonin and its receptors than in noradrenaline. Real innovation in antidepressant research is focusing on other, non-monoamine approaches, including neurokinins, excitatory amino acids, neuronal plasticity, gene transcription factors, and the HPA axis. Whether it leads to true third generation antidepressants, which will extend our ability to treat depression more quickly in a greater proportion of patients with improved rates of response and remission, is still to be seen. Early indications are that the first neurokinin antagonists are no faster or better than SSRIs in efficacy, and may not be developed further, but that glucocorticoid antagonists may be superior in psychotic depression, melancholia, and in those patients with disturbed cortisol. There is certainly a place in the armamentarium for new antidepressants, but it is unlikely that they will be agents that only enhance central noradrenergic function.
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